Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference 79a457b39f
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/13 06:42.
Drug filings
18 acceptance records as first applicant, grouped into 10 source drug names. Source data as of 2026/11/13 06:42.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
Edaravone and Dexborneol Concentrated Solution for Injection 1 records · Latest accepted 2026/07/09
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2601643 | Generic | 2026/07/09 | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized; Jiangsu Ao Sai Kang Pharma Co., Ltd. romanized | CDE ↗ |
维生素K1片 · No verified English name 1 records · Latest accepted 2025/07/23
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2502661 | Generic | 2025/07/23 | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized; Jiangsu Xuan Tai Pharma Co., Ltd. romanized | CDE ↗ |
Isavuconazonium Sulfate for Injection 1 records · Latest accepted 2024/08/02
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2402457 | Generic | 2024/08/02 | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized; Hunan Ke Lun Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Posaconazole Enteric-coated Tablets 4 records · Latest accepted 2024/07/02
Supplement · 2New drug · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2400936 | Supplement | 2024/07/02 | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized; Jiangsu Xuan Tai Pharma Co., Ltd. romanized | CDE ↗ |
| CYHB2201031 | Supplement | 2022/06/23 | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized; Jiangsu Xuan Tai Pharma Co., Ltd. romanized | CDE ↗ |
| CXHL2100031 | New drug | 2021/01/16 | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized | CDE ↗ |
| CXHL2100030 | New drug | 2021/01/16 | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized | CDE ↗ |
Sevelamer Carbonate Tablets 1 records · Latest accepted 2024/02/05
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2400212 | Supplement | 2024/02/05 | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized; Jiangsu Xuan Tai Pharma Co., Ltd. romanized | CDE ↗ |
Sitagliptin and Metformin Hydrochloride Extended-release Tablets 1 records · Latest accepted 2023/12/08
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2302684 | Supplement | 2023/12/08 | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized; Jiangsu Xuan Tai Pharma Co., Ltd. romanized | CDE ↗ |
Dapagliflozin And Metformin Hydrochloride Extended-Release Tablets 5 records · Latest accepted 2022/09/16
Generic · 5
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2201540 | Generic | 2022/09/16 | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized; Jiangsu Xuan Tai Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2201539 | Generic | 2022/09/16 | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized; Jiangsu Xuan Tai Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2201538 | Generic | 2022/09/16 | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized; Jiangsu Xuan Tai Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2201537 | Generic | 2022/09/16 | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized; Jiangsu Xuan Tai Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2201536 | Generic | 2022/09/16 | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized; Jiangsu Xuan Tai Pharma Co., Ltd. romanized | CDE ↗ |
Mesalazine Enteric-coated Tablets 1 records · Latest accepted 2022/07/29
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2201167 | Generic | 2022/07/29 | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized; Jiangsu Xuan Tai Pharma Co., Ltd. romanized | CDE ↗ |
Olaparib Tablets 2 records · Latest accepted 2022/01/27
Generic · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2200203 | Generic | 2022/01/27 | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized; Jiangsu Xuan Tai Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2200115 | Generic | 2022/01/27 | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized; Jiangsu Xuan Tai Pharma Co., Ltd. romanized | CDE ↗ |
Tofacitinib Citrate Extended Release tablets 1 records · Latest accepted 2021/05/14
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2101133 | Generic | 2021/05/14 | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized; Jiangsu Xuan Tai Pharma Co., Ltd. romanized | CDE ↗ |
Changes in the last 90 days
0 events from 2026/08/16 to 2026/11/13. CDE data as of 2026/11/13 06:42; NMPA data as of 2026/11/12 18:32.
This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
- No matching records were found in the currently loaded source data; coverage dates are listed below.
Under review
2 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/13 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Edaravone and Dexborneol Concentrated Solution for Injection | CYHS2601643 | Generic | 2026/07/09 | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized; Jiangsu Ao Sai Kang Pharma Co., Ltd. romanized | CDE ↗ |
| 维生素K1片 · No verified English name | CYHS2502661 | Generic | 2025/07/23 | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized; Jiangsu Xuan Tai Pharma Co., Ltd. romanized | CDE ↗ |
Catalogue holder records
14 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/13 06:39. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | Approval number | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets(III) | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized | Jiangsu Xuan Tai Pharma Co., Ltd. romanized | 国药准字H20244865 | 2024/09/10 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets (Ⅰ) | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized | Jiangsu Xuan Tai Pharma Co., Ltd. romanized | 国药准字H20244866 | 2024/09/10 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Olaparib Tablets | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized | Jiangsu Xuan Tai Pharma Co., Ltd. romanized | 国药准字H20244040 | 2024/06/18 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Olaparib Tablets | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized | Jiangsu Xuan Tai Pharma Co., Ltd. romanized | 国药准字H20244039 | 2024/06/18 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| 美沙拉秦肠溶缓释片 · No verified English name | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized | Jiangsu Xuan Tai Pharma Co., Ltd. romanized | 国药准字H20243129 | 2024/01/30 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Tofacitinib Citrate Extended Release tablets | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized | Jiangsu Xuan Tai Pharma Co., Ltd. romanized | 国药准字H20234260 | 2023/10/12 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| 西格列汀二甲双胍缓释片(II) · No verified English name | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized | Jiangsu Xuan Tai Pharma Co., Ltd. romanized | 国药准字H20233644 | 2023/06/07 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Ursodeoxycholic Acid Capsules | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized | Jiangsu Xuan Tai Pharma Co., Ltd. romanized | 国药准字H20223527 | 2022/07/19 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Paroxetine Hydrochloride Enteric-Coated Sustained-Release Tablets | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized | Jiangsu Xuan Tai Pharma Co., Ltd. romanized | 国药准字H20223170 | 2022/03/29 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Paroxetine Hydrochloride Enteric-Coated Sustained-Release Tablets | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized | Jiangsu Xuan Tai Pharma Co., Ltd. romanized | 国药准字H20223171 | 2022/03/29 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| 盐酸安非他酮缓释片(II) · No verified English name | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized | Hangzhou Min Sheng Bin Jiang Pharmaceutical Co., Ltd. romanized | 国药准字H20213821 | 2021/10/26 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| 盐酸安非他酮缓释片(II) · No verified English name | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized | Hangzhou Min Sheng Bin Jiang Pharmaceutical Co., Ltd. romanized | 国药准字H20213820 | 2021/10/26 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Posaconazole Enteric-coated Tablets | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized | Shanghai Xuan Tai Hai Men Pharma Co., Ltd. romanized | 国药准字H20213030 | 2021/01/19 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Isavuconazonium Sulfate for Injection | Shanghai Xuan Tai Pharmaceuticals Technology Co., Ltd. romanized | Hunan Ke Lun Pharmaceutical Co., Ltd. romanized | 国药准字H20256410 | 2025/12/30 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
0 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/13 06:41.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | |||||
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
0 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/13 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | |||||
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/13 06:42
- Chemical-drug catalogue
- Last successful update: 2026/11/13 06:39
- Full API register
- Last successful update: 2026/11/13 06:41
- NMPA drug delivery notices
- Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete
First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.